Vision
Advancing Japanese Biotech Innovation Globally.
AN Venture Partners is a Tokyo and San Francisco-based multi-stage, global biotech venture capital firm specializing in bridging innovative science from Japan with the US start-up ecosystem. ANV Fund I is a USD200 million fund that closed in June 2025. The firm was established in 2022 by a group of experienced venture capitalists from Japan and the United States, who have a wealth of experience building start-ups. ANV is committed to strengthening Japan's biotech ecosystem and founded initiatives to accelerate ecosystem growth.











Japan
SOURCE
Discover innovative and underappreciated science from Japan, one of the world's leading life sciences hubs. Despite a wealth of groundbreaking research and a track record of blockbuster medicines, Japan remains an untapped source of scientific opportunity, with far fewer biotech startups than its global peers.

US
BUILD
Create and foster new startups in the US, originating from Japanese science, by leveraging the expertise and resources of the world's largest and most dynamic biotech ecosystem. By building companies in the US, AN Venture Partners maximizes value creation and capture, bridging Japanese scientific excellence with unparalleled access to talent, capital, and industry networks.

Global
FINANCE
Partner with leading global venture investors to syndicate and support each portfolio company, enabling robust capitalization and global development. AN Venture Partners works closely with blue-chip investors who accelerate growth, elevate the global profile of Japanese science, and drive long-term value creation across the portfolio.
Press Release
Expert Perspectives on Science, Innovation, and Investment.
Press List
Press Release
Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO
Boston, Mass., Apr. 10, 2024
Learn More
Press Release
AN Venture Partners Announce the Addition of Takashi Futami, Ph.D. as Partner
San Francisco, Jul. 26, 2023
Learn More
Press Release
Typewriter Therapeutics secures $5 million in financing; RA Capital Management and AN Ventures lead investor syndicate
Cambridge, Mass., Feb. 27, 2024
Learn More
Press Release
AN Venture Partners Selected as a Certified Venture Capital Provider for AMED’s Strengthening Program for Pharmaceutical Startup Ecosystem Initiative
Tokyo, Feb. 29, 2024
Learn More
Our Team
A Highly Experienced Core Team Leveraging a Global Network of Experts
